Gossamer Bio (GOSS) Competitors $0.84 0.00 (-0.11%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends GOSS vs. CRON, ERAS, EOLS, RAPP, DNTH, AUTL, PRTA, OCS, CGEM, and TECXShould you be buying Gossamer Bio stock or one of its competitors? The main competitors of Gossamer Bio include Cronos Group (CRON), Erasca (ERAS), Evolus (EOLS), Rapport Therapeutics (RAPP), Dianthus Therapeutics (DNTH), Autolus Therapeutics (AUTL), Prothena (PRTA), Oculis (OCS), Cullinan Therapeutics (CGEM), and Tectonic Therapeutic (TECX). These companies are all part of the "pharmaceutical products" industry. Gossamer Bio vs. Cronos Group Erasca Evolus Rapport Therapeutics Dianthus Therapeutics Autolus Therapeutics Prothena Oculis Cullinan Therapeutics Tectonic Therapeutic Gossamer Bio (NASDAQ:GOSS) and Cronos Group (NASDAQ:CRON) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, risk, community ranking, media sentiment, valuation, institutional ownership, profitability, analyst recommendations and dividends. Does the MarketBeat Community prefer GOSS or CRON? Cronos Group received 313 more outperform votes than Gossamer Bio when rated by MarketBeat users. However, 66.23% of users gave Gossamer Bio an outperform vote while only 61.13% of users gave Cronos Group an outperform vote. CompanyUnderperformOutperformGossamer BioOutperform Votes15166.23% Underperform Votes7733.77% Cronos GroupOutperform Votes46461.13% Underperform Votes29538.87% Does the media prefer GOSS or CRON? In the previous week, Cronos Group had 2 more articles in the media than Gossamer Bio. MarketBeat recorded 2 mentions for Cronos Group and 0 mentions for Gossamer Bio. Cronos Group's average media sentiment score of 0.50 beat Gossamer Bio's score of 0.00 indicating that Cronos Group is being referred to more favorably in the news media. Company Overall Sentiment Gossamer Bio Neutral Cronos Group Neutral Is GOSS or CRON more profitable? Gossamer Bio has a net margin of 0.00% compared to Cronos Group's net margin of -42.65%. Cronos Group's return on equity of -2.56% beat Gossamer Bio's return on equity.Company Net Margins Return on Equity Return on Assets Gossamer BioN/A -127.28% -22.12% Cronos Group -42.65%-2.56%-2.47% Which has better earnings & valuation, GOSS or CRON? Cronos Group has higher revenue and earnings than Gossamer Bio. Cronos Group is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGossamer Bio$105.32M1.81-$179.82M-$0.32-2.63Cronos Group$111.23M6.70-$73.96M-$0.13-15.00 Do insiders and institutionals hold more shares of GOSS or CRON? 81.2% of Gossamer Bio shares are owned by institutional investors. Comparatively, 8.7% of Cronos Group shares are owned by institutional investors. 5.0% of Gossamer Bio shares are owned by insiders. Comparatively, 6.9% of Cronos Group shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Do analysts prefer GOSS or CRON? Gossamer Bio presently has a consensus target price of $9.20, indicating a potential upside of 995.24%. Cronos Group has a consensus target price of $3.00, indicating a potential upside of 53.85%. Given Gossamer Bio's stronger consensus rating and higher possible upside, analysts clearly believe Gossamer Bio is more favorable than Cronos Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gossamer Bio 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Cronos Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Which has more risk and volatility, GOSS or CRON? Gossamer Bio has a beta of 1.85, suggesting that its stock price is 85% more volatile than the S&P 500. Comparatively, Cronos Group has a beta of 0.99, suggesting that its stock price is 1% less volatile than the S&P 500. SummaryCronos Group beats Gossamer Bio on 10 of the 18 factors compared between the two stocks. Ad Crypto Swap ProfitsURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.>> Register for the Workshop Now Get Gossamer Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for GOSS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GOSS vs. The Competition Export to ExcelMetricGossamer BioPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$190.35M$6.57B$5.12B$9.07BDividend YieldN/A2.98%4.91%4.22%P/E Ratio-2.6310.5991.3417.19Price / Sales1.81195.381,116.63116.80Price / CashN/A57.1642.5837.86Price / Book3.005.104.794.78Net Income-$179.82M$151.51M$120.07M$225.60M7 Day Performance-9.68%-2.14%-1.90%-1.24%1 Month Performance26.39%-3.13%11.43%3.06%1 Year Performance-6.06%11.51%30.59%16.50% Gossamer Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GOSSGossamer Bio3.6117 of 5 stars$0.84-0.1%$9.20+995.2%-1.4%$190.35M$105.32M-2.63180CRONCronos Group1.8381 of 5 stars$1.94+0.3%$3.00+55.0%+4.8%$739.75M$87.24M-15.19356News CoverageERASErasca2.17 of 5 stars$2.60+1.6%$5.90+126.9%+35.8%$735.09MN/A-3.08126News CoveragePositive NewsGap UpEOLSEvolus3.8301 of 5 stars$11.53+0.2%$23.00+99.5%+12.5%$730.08M$202.09M-12.73170RAPPRapport Therapeutics1.5264 of 5 stars$19.70+5.0%$35.00+77.7%N/A$720.63MN/A0.00N/ADNTHDianthus Therapeutics1.3413 of 5 stars$24.21+1.7%$46.43+91.8%+213.2%$716.62M$2.83M-9.5280Analyst ForecastNews CoverageAUTLAutolus Therapeutics2.5563 of 5 stars$2.62+5.2%$10.40+296.9%-58.4%$697.16M$1.70M-2.06330PRTAProthena1.6262 of 5 stars$12.90+0.9%$61.83+379.3%-58.8%$694.14M$133.35M-5.16173Analyst ForecastNews CoverageOCSOculis1.6512 of 5 stars$17.06-0.2%$29.20+71.2%+57.2%$691.00M$980,000.00-8.852CGEMCullinan Therapeutics1.7981 of 5 stars$11.85+0.9%$31.67+167.2%+32.7%$690.00M$18.94M-4.1430News CoverageTECXTectonic Therapeutic2.9329 of 5 stars$46.27+2.1%$72.25+56.1%N/A$682.62MN/A-7.70120 Related Companies and Tools Related Companies CRON Competitors ERAS Competitors EOLS Competitors RAPP Competitors DNTH Competitors AUTL Competitors PRTA Competitors OCS Competitors CGEM Competitors TECX Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:GOSS) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gossamer Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Gossamer Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GOSS Stock Alerts